CARGO Therapeutics Under Investigation for Securities Violations
LOS ANGELES, Feb. 6, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, has announced that it is looking into claims for investors of CARGO Therapeutics, Inc. (“CARGO” or “the Company”) CRGX concerning possible violations of securities laws.
Focus of the Investigation
The investigation is centered around whether CARGO made false or misleading statements or failed to share important information with investors. Recently, on January 29, 2025, the Company announced its decision to stop the FIRCE-1 trial, which was a Phase 2 clinical study of firi-cel aimed at patients with large B-cell lymphoma (LBCL) who had relapsed or showed resistance to CD19 CAR T-cell therapy. They noted, “Based on an ad hoc analysis of FIRCE-1 prompted by recent safety events, the Company believes the results do not support a competitive benefit-risk profile of firi-cel for the intended patient population.”
Options for Affected Shareholders
Shareholders who experienced a financial setback are encouraged to seek more information. Click here to participate.
Contact Information
Interested parties can reach out to Brian Schall of the Schall Law Firm at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, by calling 310-301-3335. Alternatively, you can visit their website at www.schallfirm.com, or email at [email protected].
About the Schall Law Firm
The Schall Law Firm assists investors worldwide and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be viewed as Attorney Advertising in certain regions under applicable laws and ethical guidelines.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/crgx-investors-have-opportunity-to-join-cargo-therapeutics-inc-securities-fraud-investigation-with-the-schall-law-firm-302370572.html
SOURCE The Schall Law Firm
